Clinical core. The Clinical Core will support investigators of the Program for Excellence in Gene Therapy with the formulation, execution and analysis of their clinical gene therapy trials. During protocol formulation the Clinical Core will provide biostatistical support in designing the protocol, as well as advise an active role in the preparation of study manuals, case report forms, regulatory notebooks, statistical analysis plans and monitoring plans. The Clinical Core will assist investigators in preparing their protocols for presentation to the Data Safety Monitoring Board (DSMB) and the Gene Therapy Ethics and Conflict of Interest Board. Prior to beginning the trial an agreement will be set in place which clearly delineates the responsibilities of the study Principal Investigator and the responsibilities of the Clinical Core. During execution of the trial the Clinical Core will provide logistical support for patient travel arrangements, blood draws, sample collections, procedures and other testing. In addition the Clinical Core will verify informed consent, complete case report forms and assist with data management. A key function of the Clinical Core will be in contract with external monitors for each of the clinical protocols to assure that studies are conducted in accordance with the study protocol. A quality assurance auditor will provide oversight of monitoring, will educate staff regarding regulatory requirements, and will assure that all trials are conducted strictly in compliance with institutional and governmental regulations. Following study completion the Clinical Core will assist with data management and analyses.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01HL066947-01
Application #
6365276
Study Section
Special Emphasis Panel (ZHL1-CSR-C (S2))
Project Start
2000-09-28
Project End
2005-08-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2000
Total Cost
$256,500
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Yannaki, Evangelia; Papayannopoulou, Thalia; Jonlin, Erica et al. (2012) Hematopoietic stem cell mobilization for gene therapy of adult patients with severe ?-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther 20:230-8
Kiem, Hans-Peter; Ironside, Christina; Beard, Brian C et al. (2010) A retroviral vector common integration site between leupaxin and zinc finger protein 91 (ZFP91) observed in baboon hematopoietic repopulating cells. Exp Hematol 38:819-22, 822.e1-3
Yannaki, Evangelia; Emery, David W; Stamatoyannopoulos, George (2010) Gene therapy for ?-thalassaemia: the continuing challenge. Expert Rev Mol Med 12:e31
Yannaki, Evangelia; Stamatoyannopoulos, George (2010) Hematopoietic stem cell mobilization strategies for gene therapy of beta thalassemia and sickle cell disease. Ann N Y Acad Sci 1202:59-63
Stirewalt, D L; Choi, Y E; Sharpless, N E et al. (2009) Decreased IRF8 expression found in aging hematopoietic progenitor/stem cells. Leukemia 23:391-3
Berger, Carolina; Jensen, Michael C; Lansdorp, Peter M et al. (2008) Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118:294-305
Stirewalt, Derek L; Meshinchi, Soheil; Kopecky, Kenneth J et al. (2008) Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer 47:8-20
Beard, Brian C; Dickerson, David; Beebe, Kate et al. (2007) Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells. Mol Ther 15:1356-65
Halbert, Christine L; Lam, Siu-Ling; Miller, A Dusty (2007) High-efficiency promoter-dependent transduction by adeno-associated virus type 6 vectors in mouse lung. Hum Gene Ther 18:344-54
Berger, Carolina; Berger, Michael; Feng, Junli et al. (2007) Genetic modification of T cells for immunotherapy. Expert Opin Biol Ther 7:1167-82

Showing the most recent 10 out of 37 publications